RedHill Biopharma Announces Full Results from Positive MAP US Phase 3 Study and Supportive Top-Line Results from MAP US2 Open-Label Extension Study with RHB-104 in Crohn’s Disease

Pat Purcell
Meeting Engagement

Daniel Sontupe
Market Access

Suma Ramadas, PhD
Medical Affairs

Stacey Gandler
Brand Nourishment

Amy Giles
Increasing Engagement

Brenda Snow
Authentic Patient Voice

Paul Theisen
Patient Acquisition

Frank Burrell
Scientific Storytelling

Matt Turner
Patient Affordability

Liz Kane
Impactful Strategy

Joey Cohen
Medication Adherence

Matthew Durham
Omnidynamic Marketing

David Linetsky
Point-of-Care Marketing

Bud Bilanich
Success Coach